RELTECIMOD

Drug Overview

RELTECIMOD (formerly known as AB103) is an experimental, high-potency IMMUNOMODULATOR and a specialized synthetic PEPTIDE within the IMMUNOLOGY drug category. Classified as a T-CELL LINEAGE-SPECIFIC MODULATOR, it is being researched as a TARGETED THERAPY for the treatment of NECROTIZING SOFT TISSUE INFECTIONS (NSTI), a group of life-threatening conditions often referred to as “flesh-eating bacteria.”

• Generic Name: Reltecimod
• Developmental Code: AB103
• Drug Class: CD28 Antagonist; IMMUNOMODULATOR
• Route of Administration: Intravenous (IV) Infusion
• FDA Status: Currently in clinical development (Phase 3); it has received Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of NSTI.

Reltecimod is designed to address the “cytokine storm” that occurs during severe, invasive infections. In NSTI, mortality and tissue loss are often driven by an overactive immune response rather than the bacteria alone. Reltecimod aims to dampen this response without causing total immunosuppression, allowing the body to fight the infection while preventing self-inflicted systemic damage.

What Is It and How Does It Work?

Reltecimod functions through SELECTIVE CYTOKINE INHIBITION by targeting the “Signal 2” pathway of T-cell activation. In NSTI, bacteria such as Streptococcus pyogenes release superantigens that force an unnatural, massive activation of the immune system.

Molecular and Cellular Level Action

The drug interrupts the lethal inflammatory cascade through a specific molecular blockade:

1. CD28 Targeting: Reltecimod is a synthetic peptide that mimics a specific domain of the human CD28 molecule, which is a key costimulatory receptor on T-cells.
2. Competitive Inhibition: It binds to the superantigens (exotoxins) produced by the bacteria. This prevents the superantigens from attaching to the CD28 receptor on T-cells.
3. Pathway Interruption: By blocking this “second signal,” the drug prevents T-cells from becoming hyper-activated and producing an uncontrolled surge of inflammatory markers.
4. Dampening the Cytokine Storm: It significantly reduces the levels of pro-inflammatory cytokines, including TNF-alpha, Interleukin-1 (IL-1), and Interleukin-6 (IL-6).
5. Organ Preservation: By modulating the immune response, the drug aims to prevent septic shock and multi-organ failure, reducing the risk of mortality and the need for extensive amputations.

Clinical Indications Under Research

Primary Research Indication: Necrotizing Soft Tissue Infections (NSTI)

Reltecimod is being studied as an adjunct (add-on) therapy to the current standard of care, which includes:

• Surgical Debridement: The emergency removal of dead and infected tissue.
• Broad-Spectrum Antibiotics: To kill the underlying bacterial pathogens.
• Supportive Care: ICU management for organ failure and sepsis.

Other Potential Research Areas

• Abdominal Sepsis: Investigating if CD28 modulation can improve survival in severe peritonitis.
• Acute Kidney Injury (AKI): Researching the drug’s ability to protect renal function by preventing cytokine-induced damage during severe systemic inflammation.

Dosage and Administration Protocols (Experimental)

In clinical trials such as the ACCUTE and ACCUTE-t studies, Reltecimod is administered as a single-dose treatment to patients immediately following diagnosis.

Administration Details

• Preparation: The drug is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with sterile saline.
• Synergy: It is designed to be given in the Emergency Room or Intensive Care Unit (ICU) as soon as surgical intervention is initiated.

Clinical Efficacy and Research Results

The efficacy of Reltecimod has been evaluated in Phase 2 and Phase 3 trials, with data collection and long-term follow-up continuing through 2026.

Numerical Research Data

• Organ Failure Resolution: In the Phase 3 trial, patients treated with Reltecimod showed a higher rate of “Total Organ Failure Assessment” (SOFA) score resolution by Day 14 compared to the placebo group.
• Clinical Success: Research indicated an improvement in a composite endpoint of survival, lack of further tissue loss, and resolution of organ dysfunction in treated patients.
• Discharge Status: Data suggests that patients receiving the drug were more likely to be discharged to home rather than to long-term rehabilitation or skilled nursing facilities.

Recent Research (2025-2026)

Current research in PRECISION IMMUNOLOGY is exploring “Biomarker-Driven Dosing.” 2026 studies are investigating if measuring a patient’s baseline Interleukin-6 levels can predict who will benefit most from early Reltecimod administration. Additionally, researchers are exploring “Repeat Dosing” for patients who remain in a hyper-inflammatory state 48 hours after the initial surgery.

Disclaimer: The research mentioned regarding “Biomarker-Driven Dosing” (using IL-6 levels to predict response) and the investigation into “Repeat Dosing” for sustained hyper-inflammatory states is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios. 

Safety Profile and Side Effects (Experimental)

Based on data from clinical trials, Reltecimod appears to have a favorable safety profile, particularly due to its single-dose administration.

Observed Side Effects

• Hypotension: Mild, transient drops in blood pressure have been reported during the 10-minute infusion.
• Nausea and Vomiting: General gastrointestinal distress reported in a small percentage of patients.
• Headache: Mild and resolving without medical intervention.

Clinical Considerations

• Non-Immunosuppressive: Unlike corticosteroids or anti-TNF biologics, Reltecimod does not appear to increase the risk of secondary “opportunistic” infections because it modulates rather than shuts down the immune response.
• Renal Safety: Trials have specifically monitored kidney function and have not found evidence of drug-induced nephrotoxicity.

Patient Management and Research Protocols

Pre-treatment Assessment

• Surgical Confirmation: Clinical and surgical diagnosis of necrotizing infection is required.
• Weight Measurement: An accurate weight is necessary to calculate the 0.5 mg/kg dose.
• Baseline Organ Function: Assessment of kidney and liver function prior to the start of the “cytokine storm.”

Monitoring and Precautions

• Vital Signs: Continuous monitoring of blood pressure and heart rate during the IV infusion.
• Wound Tracking: Close observation of the surgical site to ensure the infection has stopped “creeping” or spreading.
• Lifestyle (Post-Recovery):
  • Rehabilitation: Survivors of NSTI often require extensive physical and occupational therapy.
  • Psychological Support: PTSD screening is recommended due to the traumatic nature of the infection and the potential for life-altering surgeries.

Do’s and Don’ts

• DO administer the drug as early as possible; research suggests the greatest benefit occurs when given within 6 hours of diagnosis.
• DO continue aggressive surgical debridement; the drug is an adjunct to, not a replacement for, surgery.
• DO maintain adequate hydration to support kidney function during the septic state.
• DON’T use Reltecimod as a stand-alone therapy; it must be used as part of a multi-modal approach (Surgery + Antibiotics + Reltecimod).
• DON’T expect the drug to clear the bacteria; its only role is to manage the host’s immune response.
• DON’T ignore signs of secondary infections, even if the primary necrotizing site appears to be healing.

Legal Disclaimer

This guide is provided for informational purposes only and describes a drug currently under investigation. RELTECIMOD IS NOT YET FDA-APPROVED. Access to this medication is currently limited to patients enrolled in clinical trials. Treatment of necrotizing soft tissue infections is a medical emergency and must be managed by a specialized surgical and ICU team. Never disregard professional medical advice based on information provided in this guide.